134 related articles for article (PubMed ID: 31241492)
1. Trametinib-Associated Bradycardia.
Alhazmi L; Karim MM; Al-Sarie M; Skeel R; Karim S
Am J Ther; 2019; 26(5):e657-e659. PubMed ID: 31241492
[No Abstract] [Full Text] [Related]
2. Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
Nardin C; Colas M; Badoz M; Roche-Kubler B; Meneveau N; Puzenat E; Aubin F
Eur Heart J; 2017 Jul; 38(27):2151. PubMed ID: 28329154
[No Abstract] [Full Text] [Related]
3. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
[No Abstract] [Full Text] [Related]
4. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
6. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
[TBL] [Abstract][Full Text] [Related]
7. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Algazi AP; Othus M; Daud AI; Lo RS; Mehnert JM; Truong TG; Conry R; Kendra K; Doolittle GC; Clark JI; Messino MJ; Moore DF; Lao C; Faller BA; Govindarajan R; Harker-Murray A; Dreisbach L; Moon J; Grossmann KF; Ribas A
Nat Med; 2020 Oct; 26(10):1564-1568. PubMed ID: 33020646
[TBL] [Abstract][Full Text] [Related]
8. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
9. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
[No Abstract] [Full Text] [Related]
10. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
[No Abstract] [Full Text] [Related]
11. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
[TBL] [Abstract][Full Text] [Related]
12. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
13. [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
Lüdeke I; Terheyden P; Grisanti S; Lüke M
Ophthalmologe; 2016 Oct; 113(10):861-863. PubMed ID: 26873702
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
15. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.
Melin A; Routier E; Tissot H; Rouleau E; Robert C
Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065
[No Abstract] [Full Text] [Related]
16. Gut dysbiosis: not only with checkpoint inhibitors!
Piroth M; Frenard C; Quereux G; Khammari A; Corvec S; Dréno B
Clin Exp Dermatol; 2020 Mar; 45(2):247-249. PubMed ID: 31222907
[No Abstract] [Full Text] [Related]
17. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.
Carlino MS; Kwan V; Miller DK; Saunders CA; Yip D; Nagrial AM; Tomlinson J; Grimmond SM; Scolyer RA; Kefford RF; Biankin AV; Long GV
J Clin Oncol; 2015 Apr; 33(11):e52-6. PubMed ID: 24821886
[No Abstract] [Full Text] [Related]
18. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
19. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
[TBL] [Abstract][Full Text] [Related]
20. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
Ibrahim T; Routier E; Weill A; Baz M; Robert C
Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
[No Abstract] [Full Text] [Related]
[Next] [New Search]
